Suppr超能文献

相似文献

3
LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Acta Neuropathol Commun. 2018 May 31;6(1):45. doi: 10.1186/s40478-018-0550-0.
4
Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Adv Neurobiol. 2017;14:209-226. doi: 10.1007/978-3-319-49969-7_11.
5
LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Neurobiol Dis. 2020 Oct;144:105049. doi: 10.1016/j.nbd.2020.105049. Epub 2020 Aug 13.
7
Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
Cell Cycle. 2019 Feb;18(4):467-475. doi: 10.1080/15384101.2019.1577666. Epub 2019 Feb 6.
8
LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Curr Med Sci. 2018 Dec;38(6):1012-1017. doi: 10.1007/s11596-018-1977-z. Epub 2018 Dec 7.
9
LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
Acta Neuropathol Commun. 2019 Feb 26;7(1):28. doi: 10.1186/s40478-019-0679-5.
10
LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
Curr Protein Pept Sci. 2017;18(7):677-686. doi: 10.2174/1389203717666160311121748.

引用本文的文献

1
Accumulation of LRRK2-associated phospho-Rab12 degenerative lysosomes in tauopathies.
bioRxiv. 2025 Jun 9:2025.06.06.658328. doi: 10.1101/2025.06.06.658328.
2
Role of LRRK2 in axonal transport and Parkinson's disease.
Biochem J. 2025 Jun 25;482(13):BCJ20253133. doi: 10.1042/BCJ20253133.
3
LRRK2-mediated mitochondrial dysfunction in Parkinson's disease.
Biochem J. 2025 May 28;482(11):BCJ20253062. doi: 10.1042/BCJ20253062.
4
Roles of LRRK2 and its orthologs in protecting against neurodegeneration and neurodevelopmental defects.
Front Cell Dev Biol. 2025 Apr 30;13:1569733. doi: 10.3389/fcell.2025.1569733. eCollection 2025.
5
Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases.
Acta Neuropathol. 2025 May 2;149(1):41. doi: 10.1007/s00401-025-02871-w.
6
Lysosomal TPC2 channels disrupt Ca2+ entry and dopaminergic function in models of LRRK2-Parkinson's disease.
J Cell Biol. 2025 Jun 2;224(6). doi: 10.1083/jcb.202412055. Epub 2025 Apr 25.
7
Transcriptome signatures of human neural stem cells derived from LRRK2 gene therapeutic cells.
Sci Rep. 2025 Apr 10;15(1):12286. doi: 10.1038/s41598-025-96884-w.
8
Immune cell metabolic dysfunction in Parkinson's disease.
Mol Neurodegener. 2025 Mar 24;20(1):36. doi: 10.1186/s13024-025-00827-y.

本文引用的文献

1
Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease.
Cell Stem Cell. 2016 Dec 1;19(6):709-724. doi: 10.1016/j.stem.2016.08.002. Epub 2016 Sep 8.
3
G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
J Neurosci. 2016 Jul 13;36(28):7415-27. doi: 10.1523/JNEUROSCI.3642-15.2016.
4
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Autophagy. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356.
6
Cysteine cathepsins are essential in lysosomal degradation of α-synuclein.
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9322-7. doi: 10.1073/pnas.1500937112. Epub 2015 Jul 13.
7
Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
J Biol Chem. 2015 Aug 7;290(32):19433-44. doi: 10.1074/jbc.M115.660001. Epub 2015 Jun 15.
8
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
Neurobiol Dis. 2015 Jun;78:172-95. doi: 10.1016/j.nbd.2015.02.031. Epub 2015 Mar 31.
9
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.
Sci Transl Med. 2015 Feb 4;7(273):273ra15. doi: 10.1126/scitranslmed.aaa3634.
10
LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism.
J Cell Sci. 2015 Feb 1;128(3):541–52. doi: 10.1242/jcs.158196.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验